A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15).

MLA

Baek, Sun Kyung, et al. “A Nationwide Real-World Study for Evaluation of Effectiveness and Safety of T-DM1 in Patients with HER2-Positive Metastatic Breast Cancer in Korea (KCSG BR19-15).” Therapeutic Advances in Medical Oncology, Jan. 2024, pp. 1–15. EBSCOhost, https://doi.org/10.1177/17588359231225029.

APA

Baek, S. K., Jeong, J., Jung, K., Ahn, H. K., Kim, M. H., Sohn, J., Park, I. H., Ahn, J. S., Lee, D.-W., Im, S.-A., Sim, S. H., Lee, K. S., Hyun Kim, J., Shim, H.-J., Chae, Y., Koh, S.-J., Lee, H., Lee, J., Byun, J.-H., & Seol, Y. (2024). A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15). Therapeutic Advances in Medical Oncology, 1–15. https://doi.org/10.1177/17588359231225029

Chicago

Baek, Sun Kyung, Jae-ho Jeong, KyungHae Jung, Hee Kyung Ahn, Min Hwan Kim, Joohyuk Sohn, In Hae Park, et al. 2024. “A Nationwide Real-World Study for Evaluation of Effectiveness and Safety of T-DM1 in Patients with HER2-Positive Metastatic Breast Cancer in Korea (KCSG BR19-15).” Therapeutic Advances in Medical Oncology, January, 1–15. doi:10.1177/17588359231225029.